ReviewACS chemical neuroscience2025
Exploring the Application Potential of α-Synuclein Molecular Probes in Early Diagnosis of Parkinson's Disease: Focus on Imaging Methods.
Review in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to explore the potential application of α-synuclein (α-syn) molecular probes in the early diagnosis of Parkinson's disease (PD), particularly through systematic evaluation using medical imaging methods. In recent years, The abnormal aggregation of α-syn within the central nervous system is now recognized as a central driver of PD pathophysiology, solidifying its role as a critical diagnostic and prognostic biomarker. Early diagnosis of PD is critical for enabling precision therapeutic interventions and mitigating neurodegenerative progression, thereby enhancing long-term functional outcomes and the quality of life. However, challenges remain in clinical practice, particularly concerning the late timing of diagnosis and the lack of specific biomarkers. By analyzing the existing literature, we will assess the effectiveness of different imaging techniques combined with α-syn probes and discuss their advantages and limitations in clinical applications. These imaging methods can provide visualization of early pathological changes, helping to improve the recognition rate of PD. Finally, we emphasize the importance of future research to explore new molecular probes and imaging technologies that can improve early diagnosis rates and treatment outcomes for PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.